CONFIDENCE: SGLT2i and Finerenone Effective, Safe to Initiate Simultaneously in CKD
Combination therapy with finerenone and empagliflozin significantly reduces urinary albumin levels in CKD patients.
Related Articles
European Renal Association
HCPLive is a clinical news and information portal, offering physicians specialty and disease-specific resources, conference coverage, and interviews.
Study Highlights Cardiopulmonary Benefits of GLP-1 RAs in Patients with Diabetes, OSA
New research has indicated that glucagon-like peptide-1 receptor agonists result in lower all-cause mortality and risk of cardiovascular events in patients with concurrent sleep apnea…
Kidney Compass: CONFIDENCE Trial at ERA 2025, with Rajiv Agarwal, MD, MS
Brendon Neuen, MBBS, PhD, is joined by Rajiv Agarwal, MD, MS to explore the concept of simultaneous initiation of SGLT2i and nsMRA in CKD and…
Combination GIP/GLP-1 Agonism More Effectively Prevents Cardiovascular Events
Investigators compared the efficacy of tirzepatide and liraglutide in lowering rates of all-cause mortality in patients with obesity and sleep apnea.
Kidney Compass: CONFIDENCE Trial at ERA 2025, with Rajiv Agarwal, MD, MS
Brendon Neuen, MBBS, PhD, is joined by Rajiv Agarwal, MD, MS to explore the concept of simultaneous initiation of SGLT2i and nsMRA in CKD and…
Psychosocial Burdens of Atopic Dermatitis, with Mona Shahriari, MD
In this interview with Shahriari at RAD 2025, she highlights some of the most significant burdens that patients and caregivers face with atopic dermatitis.
Kidney Compass: CONFIDENCE Trial at ERA 2025, with Rajiv Agarwal, MD, MS
Brendon Neuen, MBBS, PhD, is joined by Rajiv Agarwal, MD, MS to explore the concept of simultaneous initiation of SGLT2i and nsMRA in CKD and…
Transfusion Strategies Show No QOL Improvement in Anemia Patients
A recent analysis reveals no significant difference between restrictive and liberal transfusion strategies on quality of life in patients with myocardial infarction and anemia.
Recent FDA Approvals for Atopic Dermatitis, with Jonathan Silverberg, MD, PhD, MPH
In this Q&A interview, Silverberg highlighted takeaways from his talk at RAD 2025 on recent FDA approvals for atopic dermatitis.
Pegcetacoplan Sustains Proteinuria Reductions in C3G, IC-MPGN at 52 Weeks
52-week data from the VALIANT program shed further light on the potential of pegcetacoplan in C3G and IC-MPGN.